Navigation Links
ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohn's Disease
Date:6/12/2008

Company Also Reports Significant Progress in Advancing Second-Generation

CCR9 Drug towards Clinic

MOUNTAIN VIEW, Calif., June 12 /PRNewswire/ -- ChemoCentryx, Inc., today announced the completion of enrollment of 436 patients in the company's PROTECT-1 (the Prospective Randomized Oral Therapy Evaluation in Crohn's disease Trial), a Phase II/III clinical trial of Traficet-EN(TM) (CCX282-B) in patients with moderate-to-severe Crohn's disease. This innovative clinical trial comprises three discrete phases which allows for evaluation of efficacy and safety of Traficet-EN in inducing a clinical response or remission, as well as maintaining response/remission in Crohn's disease over a combined total of 12 months. Traficet-EN is an orally-active inhibitor of the chemokine receptor known as 'CCR9', which is selectively expressed by inflammatory T cells to migrate to the digestive tract in a process that ultimately results in the persistent inflammation underlying the disease. Targeting the CCR9 chemokine receptor represents a novel approach for the treatment of Crohn's disease and other inflammatory disorders of the gastrointestinal system. The company is on track to report data from the induction phase of this trial in the fourth quarter of 2008.

PROTECT-1 is a randomized, placebo-controlled, double-blind study that includes a 12-week 'Induction Period', during which patients with moderate-to-severe Crohn's disease will receive either Traficet-EN or a placebo in order to evaluate the drug's ability to induce a clinical response or remission. The induction phase of the study is followed by a four-week, open label 'Active Period', during which all subjects receive Traficet-EN. Patients who achieve a pre-specified reduction in disease severity are re-randomized to active drug or placebo for an additional 36-week 'Maintenance Period', thereby permitting an evaluation of the drug's ability to maintain a treatment response. The prim
'/>"/>

SOURCE ChemoCentryx, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354
2. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
5. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
6. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
7. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
8. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
9. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
10. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
11. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 /PRNewswire-iReach/ -- ChinaMarketResearchReports.com adds ... its store . (Photo: http://photos.prnewswire.com/prnh/20140115/MN46792 ... upgrade and policy support, China,s ... years, with total market size rising from 3.28 billion ...
(Date:1/15/2014)... , Jan. 15, 2014  Novation, the leading health care ... new IT value-added reseller (VAR) national contracts that expand ... and services at lower costs. These include manufacturer product ... as initiative assistance and ongoing IT consulting support. ...
(Date:1/15/2014)... YORK , January 15, 2014 ... Ltd., the exclusive worldwide distributor of highly sophisticated agro-breeding ... on January 7, 2014, the Company,s board of directors ... Weiner as its new member of the board. ...
Breaking Medicine Technology:Orthopedic Instrument Industry in China Markets Forecast to 2015 2Orthopedic Instrument Industry in China Markets Forecast to 2015 3New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3
(Date:7/9/2014)... was told she had an aneurysm, she figured an invasive ... "I was devastated," said Wakulich, who is 56 years old ... a serious diagnosis. Then I met Dr. Bernard Bendok who ... invasive procedure. It was something I didn,t even know was ... U.S. clinical trial to evaluate the safety and effectiveness of ...
(Date:7/9/2014)... the most common type of lung cancer, researchers have ... role in forming tumors. The new knowledge may expand ... genetic changes already are available or are in clinical ... investigators from The Cancer Genome Atlas (TCGA), including researchers ... Harvard Medical School and other institutions, studied tumors from ...
(Date:7/9/2014)... have found that fecal transplantation is effective and safe ... This is the result of a study led by ... Women,s Gastrointestinal Medicine at The Women,s Medicine Collaborative. The ... advance of print in the American Journal of ... C. diff , has increased to epidemic proportions over ...
(Date:7/9/2014)... personal and subjective, the human brain turns them ... across different senses, situations and even people, reports ... Anderson. , "We discovered that fine-grained patterns of ... of the brain associated with emotional processing, act ... subjective feeling," says Anderson, associate professor of human ...
(Date:7/9/2014)... NEW YORK (July 8, 2014) Researchers from ... College of Medicine of Yeshiva University will present ... being held July 12 July 17 in Copenhagen, ... triggers that could prompt transition from cognitive normality to ... of the Einstein Aging Study , established in ...
Breaking Medicine News(10 mins):Health News:New type of stent could help some brain aneurysm patients 2Health News:Lung cancer study hints at new treatments 2Health News:Women's Medicine Collaborative examines safety of fecal transplant to treat C. difficile 2Health News:Study cracks how the brain processes emotions 2Health News:Investigators from Montefiore and Einstein to present data at 2014 Alzheimer's Association International Conference 2Health News:Investigators from Montefiore and Einstein to present data at 2014 Alzheimer's Association International Conference 3
... new set of strategies released today by the Commonwealth ... dramatically improve how the U.S. health care system serves ... or members of racial and ethnic minority groups. ... Framework to Achieve High Performance Health Care for Vulnerable ...
... A new study finds liver cancer incidence rates continue to increase ... and are decreasing in some of the highest risk countries of ... as high as those in Africa and more than four times ... published in an upcoming issue of Cancer Epidemiology Biomarkers and ...
... diagnosing sinusitis is presented in a new thesis from Lund University. ... and the costs of the disease to society. Sinusitis ... and a chronic form. In Europe, over nine per cent of ... the thesis is Pernilla Sahlstrand Johnson, a PhD student and ear, ...
... HealthDay Reporter , THURSDAY, Oct. 6 (HealthDay News) -- Indoor tanning ... previously believed. New research published online Oct. 6 in the ... of ultraviolet rays used in tanning beds -- UVA1 -- may ... to the cancer-causing changes caused by UV rays. ...
... marijuana plant could prevent the onset of pain associated ... cancer patients, according to researchers at Temple University,s School ... Prevents the Development of Cold and,Mechanical Allodynia in Paclitaxel-Treated ... Analgesia . The researchers developed animal models and ...
... 6 October, 2011, Bad Gastein, Austria Globally, people believe that ... health as do health care providers, according to the Edelman ... believe that their friends and family have the most impact ... than a third (36%) believe friends and family have the ...
Cached Medicine News:Health News:Strategy for improving health care for uninsured, low-income, and minorities in the US 2Health News:Strategy for improving health care for uninsured, low-income, and minorities in the US 3Health News:Strategy for improving health care for uninsured, low-income, and minorities in the US 4Health News:Strategy for improving health care for uninsured, low-income, and minorities in the US 5Health News:Study finds liver cancer increasing in low risk countries, decreasing in high risk countries 2Health News:New method to diagnose sinusitis could reduce use of antibiotics 2Health News:Tanning Beds May Be Even Riskier Than Thought 2Health News:Tanning Beds May Be Even Riskier Than Thought 3Health News:Marijuana component could ease pain from chemotherapy drugs 2Health News:Friends and family as responsible as health-care professionals for personal health, global survey 2
... L/min of Type I ultrapure water, , ... Plus System is designed to provide the ... pretreated by reverse osmosis, distillation or deionization. ... quality which exceeds Type I ASTM/CAP/NCCLS specifications.,The ...
... Synergy systems produce ultrapure water from pre-treated water ... L/min to meet the basic needs of scientific ... UV lamp (185 nm and 254 nm) to ... (< 5 ppb TOC when fed by Elix ...
... UniBloc weighing mechanism for speed, ... stability control, analog display modes, multiple ... percent measure functions, auto print, and ... data from built-in clock. Built-in, ...
... speed, stability and durability. Back-lighted Display. ... multiple units of measure, piece counting ... and GLP/GMP/ISO output including date and ... calibration with external weights only (selectable ...
Medicine Products: